	US 11,730,795 B2
	Pharmaceuticals and dosing means for human aging reversal
Gregory M. Fahy, Norco, CA (US); and Robert T. Brooke, Manhattan Beach, CA (US)
Assigned to INTERVENE IMMUNE INC., Manhattan Beach, CA (US)
Appl. No. 16/637,502
Filed by INTERVENE IMMUNE, INC., Manhattan Beach, CA (US)
PCT Filed Aug. 7, 2018, PCT No. PCT/US2018/045684 § 371(c)(1), (2) Date Feb. 7, 2020, PCT Pub. No. WO2019/032627, PCT Pub. Date Feb. 14, 2019.
Claims priority of provisional application 62/543,269, filed on Aug. 9, 2017.
Prior Publication US 2020/0254066 A1, Aug. 13, 2020
Int. Cl. A61K 38/27 (2006.01); A61K 45/06 (2006.01); C07K 14/61 (2006.01); A61K 31/5685 (2006.01)

CPC A61K 38/27 (2013.01) [A61K 31/5685 (2013.01)]

4 Claims

1. A method for the reversal of human aging, comprising administering a combination of growth hormone (GH), dehydroepiandrosterone, and metformin so as to result in reversal of epigenetic age and the age-related increase in prostate cancer risk as indicated by prostate specific antigen (PSA) levels or the percent of free PSA or the ratio of PSA to percent of free PSA or its reciprocal, wherein

GH is administered at a dose of 0.01-0.02 mg/kg for 1-6 weeks;

GH, metformin, and DHEA doses gradually increase over the first 60 days of therapy; and/or

GH, DHEA, and metformin are administered simultaneously or within 2 hours of one another.